US2009281022A1PendingUtilityA1
Method for Producing Factor VII Glycoforms
Est. expiryOct 2, 2020(expired)· nominal 20-yr term from priority
A61P 7/04A61K 38/00G01N 2400/02C12N 9/6437C12Y 304/21021A61K 38/4846C12P 21/02A61K 38/16
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.
Claims
exact text as granted — not AI-modified1 . A method for large-scale production of Factor VII or a Factor VII-related polypeptide, comprising the steps of:
(i) propagating a large-scale culture of mammalian cells in medium lacking animal-derived components until the large-scale culture cells reach a second predetermined density, said large-scale culture having been created by a method comprising:
inoculating mammalian cells expressing Factor VII or a Factor VII-related polypeptide into a seed culture vessel containing medium lacking animal-derived components;
propagating the inoculated cells at least until the cells have reached a first predetermined density to form a seed culture,
transferring the seed culture to a large-scale culture vessel containing medium lacking animal derived components to form said large-scale culture;
(ii) maintaining the large-scale culture in medium lacking animal-derived components under conditions appropriate for Factor VII expression, thereby causing the cells to produce Factor VII or a Factor VII-related polypeptide, and (iii) recovering the produced Factor VII or Factor VII-related polypeptide from the maintained culture.
2 . A method as defined in claim 1 , wherein said cells are CHO cells.
3 . A method as defined in claim 1 , wherein said Factor VII has a glycosylation pattern different from both Factor VII produced in vivo and Factor VII produced in BHK cells.
4 . A method as defined in claim 1 , wherein said seed culture has been transferred to and propagated in one or more intermediate size vessels of progressively larger size prior to being transferred to said large scale vessel.
5 . A method as defined in claim 1 , wherein the cells have been rendered suspension culture competent prior to being inoculated into the seed vessel.
6 . A method as defined in claim 1 , wherein the cells have been adapted to grow in medium lacking animal-derived components prior to said inoculation.
7 . A method as defined in claim 1 , wherein the large-scale culture is a macrocarrier culture.
8 . A method as defined in claim 7 , wherein the large-scale culture is a macroporous carrier culture, said macroporous carrier bearing a positive charge.
9 . A method as defined in claim 1 , wherein the maintaining step comprises regularly harvesting a portion of the supernatant of said large-scale culture and replacing it with fresh medium lacking animal-derived components.
10 . A method as defined in claim 1 , wherein the maintaining step comprises sedimentation of the cell-containing carriers prior to said harvesting.
11 . A method as defined in claim 1 , wherein the maintaining step comprises cooling the culture to a pre-determined temperature before the sedimentation.
12 . A method as defined in claim 1 , wherein the maintaining step comprises feeding said cells with glucose.
13 . A method as defined in claim 12 , wherein feeding comprises pulse feeding from 1 to 4 times per 24-hour period.
14 . A method as defined in claim 12 , wherein said feeding comprises gradual or continuous introduction of glucose into the large scale culture.
15 . A method for large-scale production of Factor VII or a Factor VII-related polypeptide, comprising the steps of:
(i) maintaining a large-scale culture of mammalian cells having a second predetermined density in medium lacking animal-derived components under conditions appropriate for Factor VII expression, thereby causing the cells to produce Factor VII or a Factor VII-related polypeptide, said large-scale culture having been created by a method comprising:
inoculating mammalian cells expressing Factor VII or a Factor VII-related polypeptide into a seed culture vessel containing medium lacking animal-derived components;
propagating the inoculated cells at least until the cells have reached a first predetermined density to form a seed culture,
transferring the seed culture to a large-scale culture vessel containing medium lacking animal derived components to form said large-scale culture; and
(ii) recovering produced Factor VII or Factor VII-related polypeptide from the maintained culture.
16 . A method for large-scale production of Factor VII or a Factor VII-related polypeptide, comprising the steps of:
(i) maintaining a large-scale culture of mammalian cells having a second predetermined density in medium lacking animal-derived components under conditions appropriate for Factor VII expression, thereby causing the cells to produce Factor VII or a Factor VII-related polypeptide, said large-scale culture having been created by a method comprising:
inoculating mammalian cells expressing Factor VII or a Factor VII-related polypeptide into a seed culture vessel containing medium lacking animal-derived components;
propagating the inoculated cells at least until the cells have reached a first predetermined density to form a seed culture, and
(ii) transferring the seed culture to a large-scale culture vessel containing medium lacking animal derived components to form said large-scale culture.
17 . A Factor VII or Factor VII-related polypeptide produced by a method as defined in claim 1 .
18 . A Factor VII or Factor VII-related polypeptide produced by a method as defined in claim 15 .
19 . A Factor VII or Factor VII-related polypeptide produced by a method as defined in claim 16 .
20 . A preparation comprising a plurality of Factor VII or Factor VII-related polypeptides expressed by recombinant BHK or CHO cells in the presence of media lacking animal-derived components (serum-free Factor VII), wherein the Factor VII or Factor VII-related polypeptides comprise N-linked oligosaccharides chains and the oligosaccharides exhibit a glycoform pattern differing from that of the same Factor VII or Factor VII-related polypeptide expressed by the same cells in the presence of serum (serum-raised Factor VII) and from that of Factor VII purified from human plasma (native Factor VII) and wherein a percentage of oligosaccharide chains in said preparation comprise at least one sialic acid moiety, said percentage being higher than that observed in serum-raised Factor VII preparations and lower than the corresponding percentage in native Factor VII preparations, said serum-free Factor VII preparation having a higher bioavailability than the bioavailability of a serum-raised Factor VII preparation.Join the waitlist — get patent alerts
Track US2009281022A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.